Tumor size is an independent negative prognostic factor for event free survival in children with differentiated thyroid cancer

被引:10
|
作者
Parvathareddy, Sandeep Kumar [1 ]
Siraj, Abdul K. K. [1 ]
Annaiyappanaidu, Padmanaban [1 ]
Siraj, Nabil [1 ]
Haqawi, Wael [1 ]
Al-Sobhi, Saif S. S. [2 ]
Al-Dayel, Fouad [3 ]
Al-Kuraya, Khawla S. S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, Riyadh, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Dept Surg, Riyadh, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Dept Pathol, Riyadh, Saudi Arabia
来源
FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷
关键词
differentiated thyroid carcinoma; children; tumor size; event-free survival; distant metastasis; PEDIATRIC-PATIENTS; UNITED-STATES; CARCINOMA; TRENDS; ADOLESCENTS; MANAGEMENT; RECURRENCE; OUTCOMES; THERAPY; RISK;
D O I
10.3389/fendo.2022.979054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe incidence of pediatric differentiated thyroid carcinoma (DTC) is increasing. Despite the advanced disease at presentation, the overall prognosis of DTC in children is excellent. The aim of this study is to investigate the risk stratifying factors for event free survival (EFS) of pediatric DTC from Middle Eastern ethnicity. MethodsEighty-eight patients aged <= 18 years with diagnosis of primary DTC were retrospectively analyzed. Cox proportional hazards model were used to calculate Hazard Ratios (HR) and Kaplan-Meier analysis were conducted to investigate EFS. ResultsEighty-eight (23 males and 65 females) pediatric DTCs who underwent surgery and radioactive iodine therapy had been reported (median age at diagnosis 15 years; range 5.9-17.9), with lymph node metastasis (LNM) noted in 70.5% and distant metastasis in 13.6%. Mean follow-up was 8.4 years. Ten-year overall survival rate was 98.4% while 10-year EFS was 79.2%. EFS was negatively impacted by the presence of LNM, distant metastasis and tumor size >4cm. American Thyroid Association risk stratification did not impact EFS in our cohort. Multivariate analysis revealed tumor size >4cm (HR = 5.34; 95% confidence interval (CI) = 1.36 - 20.22; p = 0.0177) and distant metastasis (HR = 8.73; 95% CI = 1.48 - 60.05; p = 0.0154) as independent negative prognostic factors for EFS. ConclusionsPrimary tumor size and the presence of distant metastasis at diagnosis are the only independent prognostic risk factors for EFS in pediatric DTC in Middle Eastern ethnicity. Children with tumor size over 4cm had poor EFS, which may justify the need of more aggressive treatment and frequent follow-up.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer
    Ghosh, Raisa
    Auh, Sungyoung
    Gubbi, Sriram
    Veeraraghavan, Padmasree
    Cochran, Craig
    Shobab, Leila
    Urken, Mark L.
    Burman, Kenneth D.
    Wartofsky, Leonard
    Klubo-Gwiezdzinska, Joanna
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025, 110 (05) : e1473 - e1480
  • [22] Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer
    Liu, Lina
    Zhang, Xinyue
    Tian, Tian
    Huang, Rui
    Liu, Bin
    THYROID, 2020, 30 (07) : 1017 - 1024
  • [23] Renal tumor size is an independent prognostic factor for overall survival in von Hippel–Lindau disease
    Taekmin Kwon
    In Gab Jeong
    Sahyun Pak
    Dalsan You
    Cheryn Song
    Jun Hyuk Hong
    Hanjong Ahn
    Choung-Soo Kim
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1171 - 1177
  • [24] Prognostic analysis of recurrence in children and adolescents with differentiated thyroid cancer
    Wang Xing
    Wang Xiao-Lei
    中华医学杂志英文版, 2020, 133 (19) : 2281 - 2286
  • [25] Vascular Invasion as an Independent Prognostic Factor in Lymph Node Negative Invasive Breast Cancer
    Rezaianzadeh, Abbas
    Talei, Abdolrasoul
    Rajaeefard, Abdereza
    Hasanzadeh, Jafar
    Tabatabai, Hamidreza
    Tahmasebi, Sedigheh
    Mousavizadeh, Ali
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (11) : 5767 - 5772
  • [26] Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
    Joseph, Richard W.
    Elassaiss-Schaap, Jeroen
    Kefford, Richard
    Hwu, Wen-Jen
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Ribas, Antoni
    Hodi, F. Stephen
    Hamid, Omid
    Robert, Caroline
    Daud, Adil
    Dronca, Roxana
    Hersey, Peter
    Weber, Jeffrey S.
    Patnaik, Amita
    de Alwis, Dinesh P.
    Perrone, Andrea
    Zhang, Jin
    Kang, S. Peter
    Ebbinghaus, Scot
    Anderson, Keaven M.
    Gangadhar, Tara C.
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 4960 - 4967
  • [27] Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy
    Sobrero, S.
    Sandri, A.
    Gagliasso, M.
    Errico, L.
    Novello, S.
    Migliaretti, G.
    Stura, I.
    Leo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1080 - S1080
  • [28] Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer
    Vaisman, Fernanda
    Bulzico, Daniel Alves
    Cordeiro Noronha Pessoa, Cencita Hosannah
    Neves Bordallo, Maria Alice
    Toscano de Mendonca, Ullyanov Bezerra
    Dias, Fernando Luiz
    Coeli, Claudia Medina
    Corbo, Rossana
    Vaisman, Mario
    CLINICS, 2011, 66 (02) : 281 - 286
  • [29] Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer
    Ginzberg, Sara P.
    Sharpe, James
    Passman, Jesse E.
    Amjad, Wajid
    Wirtalla, Christopher J.
    Ballester, Jacqueline M. Soegaard
    Finn, Caitlin B.
    Mandel, Susan J.
    Kelz, Rachel R.
    Wachtel, Heather
    THYROID, 2024, 34 (08) : 980 - 989
  • [30] Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model
    Shi, Rong-liang
    Qu, Ning
    Yang, Shu-wen
    Ma, Ben
    Lu, Zhong-wu
    Wen, Duo
    Sun, Guo-hua
    Wang, Yu
    Ji, Qing-hai
    ONCOTARGETS AND THERAPY, 2016, 9 : 5015 - 5022